MarketCapExport financials
Eargo (EAR)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Eargo Financial Ratios 2022-2011 | EAR
Brief overview of Eargo's multiples and efficiency
Current figures are compared with the company's own five-year history for 2020–2022.
The latest available valuation ratios are EV/EBITDA 0.5x (median 0.5x), P/S 0.46x (median 0.31x), P/B 0.17x (median 0.14x). On average, this basket is 17.4% above its own five-year medians. The market is pricing in elevated future expectations.
End-period return metrics are ROE -156.2%, ROA -119.2%, ROCE -110.8%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
The cash conversion cycle increased 50.7 days to 32.7 days, weakening working-capital efficiency.
What the ratios show
Eargo's profile looks stretched: price anticipates improvement that current quality ratios do not yet confirm.
Annual Financial Ratios Eargo
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.1 | -0.1 | -0.4 | - | - | - | - | - | - | - | - | - |
P/S |
0.5 | 0.3 | 0.3 | - | - | - | - | - | - | - | - | - |
EPS |
-39.7 | -81.1 | -76.1 | -173.5 | -149.7 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
-53 M | -9.63 M | -156 M | 17.1 M | 121 M | - | - | - | - | - | - | - |
EBITDA per Share |
-26.8 | -78.4 | -82 | -166 | -137 | - | - | - | - | - | - | - |
EV/EBITDA |
0.5 | 0.1 | 4.8 | -0.4 | -3.9 | - | - | - | - | - | - | - |
PEG |
- | - | -4.66 | - | - | - | - | - | - | - | - | - |
P/B |
0.2 | 0.1 | 0.1 | - | - | - | - | - | - | - | - | - |
P/CF |
-0.1 | -0.1 | -0.7 | - | - | - | - | - | - | - | - | - |
ROE % |
-156.15 | -228.09 | -20.55 | 28.50 | 29.91 | - | - | - | - | - | - | - |
ROA % |
-119.24 | -98.53 | -17.13 | -162.92 | -57.24 | - | - | - | - | - | - | - |
ROCE % |
-110.81 | -226.57 | -17.98 | -878.09 | -68.07 | - | - | - | - | - | - | - |
Current Ratio |
4.2 | 1.8 | 6.0 | 0.9 | 0.3 | - | - | - | - | - | - | - |
DSO |
70.8 | 92.8 | 15.4 | 11.4 | - | - | - | - | - | - | - | - |
DIO |
85.3 | 55.2 | 46.9 | 33.3 | - | - | - | - | - | - | - | - |
DPO |
123.5 | 98.4 | 95.5 | 62.7 | - | - | - | - | - | - | - | - |
Operating Cycle |
156.2 | 148.0 | 62.3 | 44.7 | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
32.7 | 49.6 | -33.2 | -18.0 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Eargo
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.83 | -1.21 | -1.06 | - | -1.29 | -0.82 | -0.78 | - | -2.02 | -0.5 | -0.36 | - | -57.73 | -23.66 | -43.76 | - | -46.26 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.7 | -1.12 | -1.04 | - | -0.63 | -0.77 | -0.74 | - | -1.98 | -0.47 | -0.33 | - | -17.4 | -17.9 | -41.6 | - | -44.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
32.31 | -217.84 | -249.52 | -222.89 | -300.22 | -450.58 | -169.36 | -95.64 | -89.97 | -16.04 | -11.11 | -3.78 | 4.00 | 5.76 | 16.72 | 22.77 | 7.79 | 7.43 | 7.55 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-116.15 | -112.93 | -106.81 | -87.67 | -127.15 | -92.68 | -77.14 | -54.53 | -65.57 | -28.93 | -25.01 | -18.92 | -63.44 | -2.83 | -5.05 | - | -44.52 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-38.89 | -278.76 | -308.72 | -281.04 | -358.10 | -440.64 | -168.19 | -95.09 | -90.64 | -16.46 | -11.67 | -4.48 | 3.24 | -2.88 | -6.05 | - | 7.72 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
2.8 | 3.2 | 3.6 | 4.2 | 0.8 | 1.1 | 1.4 | 1.8 | 2.0 | 5.4 | 5.9 | 6.0 | 2.4 | 6.0 | 6.0 | 0.9 | 0.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
10.9 | 16.2 | 14.8 | - | 77.3 | 154.2 | 123.3 | - | - | 41.3 | 18.9 | - | 16.0 | 21.7 | 21.1 | - | 12.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
112.9 | 71.8 | 67.3 | - | 89.4 | 121.5 | 95.5 | - | 57.2 | 40.0 | 37.7 | - | 50.6 | 48.0 | 55.1 | - | 36.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
101.7 | 89.5 | 105.6 | - | 112.2 | 196.7 | 175.2 | - | 107.3 | 94.4 | 91.5 | - | 106.5 | 105.5 | 112.2 | - | 69.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
123.8 | 88.0 | 82.1 | - | 166.7 | 275.7 | 218.9 | - | 57.2 | 81.3 | 56.6 | - | 65.0 | 69.8 | 76.1 | - | 48.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
22.1 | -1.5 | -23.4 | - | 54.5 | 79.1 | 43.7 | - | -50.1 | -13.1 | -34.9 | - | -36.1 | -35.8 | -36.1 | - | -20.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Eargo, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
LivaNova PLC
LIVN
|
$ 76.5 | 0.76 % | $ 4.17 B |  Britain |
 |
Outset Medical
OM
|
$ 3.0 | 0.66 % | $ 45.6 K |  USA |
 |
Abbott Laboratories
ABT
|
$ 98.83 | 0.03 % | $ 172 B | USA |
 |
Aethlon Medical
AEMD
|
$ 6.52 | 2.19 % | $ 4.39 M | USA |
 |
AdaptHealth Corp.
AHCO
|
$ 5.64 | 0.09 % | $ 762 M | USA |
 |
Align Technology
ALGN
|
$ 145.35 | 0.93 % | $ 10.5 B | USA |
 |
Apyx Medical Corporation
APYX
|
$ 2.45 | 4.0 % | $ 101 M | USA |
 |
Accuray Incorporated
ARAY
|
$ 0.27 | 39.38 % | $ 33.1 M | USA |
 |
Alphatec Holdings
ATEC
|
$ 10.32 | 0.05 % | $ 1.55 B | USA |
 |
AxoGen
AXGN
|
$ 41.92 | 0.61 % | $ 1.93 B | USA |
 |
Butterfly Network
BFLY
|
$ 8.96 | 1.15 % | $ 2.21 B | USA |
 |
Bio-Rad Laboratories
BIO
|
$ 377.71 | 0.18 % | $ 10.3 B | USA |
 |
Bruker Corporation
BRKR
|
$ 64.75 | 0.37 % | $ 9.83 B | USA |
 |
Boston Scientific Corporation
BSX
|
$ 43.65 | 0.11 % | $ 64.6 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
$ 8.69 | 2.36 % | $ 634 M |  Israel |
 |
ClearPoint Neuro
CLPT
|
$ 12.21 | 3.74 % | $ 346 M | USA |
 |
CONMED Corporation
CNMD
|
$ 46.23 | 0.58 % | $ 1.43 B | USA |
 |
Cytosorbents Corporation
CTSO
|
$ 3.9 | 0.62 % | $ 243 M | USA |
 |
Delcath Systems
DCTH
|
$ 15.97 | 0.76 % | $ 572 M | USA |
 |
Electromed
ELMD
|
$ 28.23 | 0.11 % | $ 233 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 64.17 | 0.74 % | $ 1.9 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 86.32 | 1.43 % | $ 50.5 B | USA |
 |
Globus Medical
GMED
|
$ 74.9 | 1.22 % | $ 10.1 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.62 | 1.92 % | $ 57.8 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 16.28 | 2.27 % | $ 1.25 B | USA |
 |
Inogen
INGN
|
$ 5.27 | 1.49 % | $ 140 M | USA |
 |
InMode Ltd.
INMD
|
$ 14.17 | 0.11 % | $ 916 M | Israel |
 |
Inspire Medical Systems
INSP
|
$ 69.36 | 4.56 % | $ 2.04 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 2.4 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 86.22 | 0.25 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.35 | 0.02 % | $ 4.39 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
$ 22.27 | 0.8 % | $ 522 M | USA |
|
LENSAR
LNSR
|
$ 6.59 | 0.72 % | $ 78.8 M | USA |
 |
Pulmonx Corporation
LUNG
|
$ 1.91 | 0.25 % | $ 77.7 M | USA |
 |
Medtronic PLC
MDT
|
$ 86.29 | 0.03 % | $ 111 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.66 | 0.21 % | $ 689 M | USA |
 |
Myomo
MYO
|
$ 1.56 | 1.27 % | $ 65.3 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.69 | 5.73 % | $ 44.7 M | Israel |
 |
InspireMD
NSPR
|
$ 0.67 | 0.53 % | $ 43.1 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.41 | 4.24 % | $ 373 M |  Curacao |
 |
PAVmed
PAVM
|
$ 3.69 | 0.66 % | $ 2.47 M | USA |
 |
Penumbra
PEN
|
$ 318.34 | 0.02 % | $ 12.4 B | USA |
 |
Insulet Corporation
PODD
|
$ 130.47 | 0.26 % | $ 9.18 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.8 | 1.4 % | $ 175 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.71 | 1.09 % | $ 158 M | USA |
 |
AVITA Medical
RCEL
|
$ 11.73 | 0.17 % | $ 327 M |  Australia |
 |
Sintx Technologies
SINT
|
$ 2.23 | 9.85 % | $ 6.18 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.96 | 0.04 % | $ 23.4 B | Britain |
 |
Sensus Healthcare
SRTS
|
$ 2.99 | 0.65 % | $ 48.8 M | USA |
 |
Stryker Corporation
SYK
|
$ 275.39 | 0.26 % | $ 105 B | USA |